Neurogene Inc. Investment Income, Interest
Neurogene Inc. (NGNE) reported Investment Income, Interest of $2.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-11
- Neurogene Inc. investment income, interest for the quarter ending 2026-06-30 was $2.05M, a 30.12% decline year-over-year.
- Neurogene Inc. investment income, interest for the quarter ending 2026-03-31 was $2.26M, a 29.48% decline year-over-year.
- Neurogene Inc. investment income, interest for the quarter ending 2025-12-31 was $2.67M, a 17.75% increase year-over-year.
- Neurogene Inc. investment income, interest for the quarter ending 2025-09-30 was $2.74M, a 48.70% increase year-over-year.
- Neurogene Inc. investment income, interest for fiscal 2025 was $11.55M, a 36.38% increase from fiscal 2024.
- Neurogene Inc. investment income, interest for fiscal 2024 was $8.47M, a 186.92% increase from fiscal 2023.
- Neurogene Inc. investment income, interest for fiscal 2023 was $2.95M, a 120.72% increase from fiscal 2022.
- Neurogene Inc. investment income, interest for fiscal 2022 was $1.34M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month | Investment Income, Interest 123 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.05M 10-Q · filed 2026-08-11 | $4.31M 10-Q · filed 2026-08-11 | $6.98M derived: sum of 3 quarters · filed 2026-08-11 | $9.72M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $2.26M 10-Q · filed 2026-05-12 | $4.93M derived: sum of 2 quarters · filed 2026-05-12 | $7.67M derived: sum of 3 quarters · filed 2026-05-12 | $10.60M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $5.41M derived: sum of 2 quarters · filed 2026-03-24 | $8.34M derived: sum of 3 quarters · filed 2026-08-11 | $11.55M 10-K · filed 2026-03-24 | |
| 2025-09-30 | $2.74M 10-Q · filed 2025-11-13 | $5.67M derived: sum of 2 quarters · filed 2026-08-11 | $8.87M 10-Q · filed 2025-11-13 | $11.14M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $2.93M 10-Q · filed 2026-08-11 | $6.13M 10-Q · filed 2026-08-11 | $8.40M derived: sum of 3 quarters · filed 2026-08-11 | $10.25M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $3.21M 10-Q · filed 2026-05-12 | $5.48M derived: sum of 2 quarters · filed 2026-05-12 | $7.32M derived: sum of 3 quarters · filed 2026-05-12 | $9.35M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $2.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $4.11M derived: sum of 2 quarters · filed 2026-03-24 | $6.15M derived: sum of 3 quarters · filed 2026-03-24 | $8.47M 10-K · filed 2026-03-24 | |
| 2024-09-30 | $1.84M 10-Q · filed 2025-11-13 | $3.88M derived: sum of 2 quarters · filed 2025-11-13 | $6.20M 10-Q · filed 2025-11-13 | $6.98M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $2.04M 10-Q · filed 2025-08-11 | $4.36M 10-Q · filed 2025-08-11 | $5.14M derived: sum of 3 quarters · filed 2025-08-11 | $5.79M derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | $2.32M 10-Q · filed 2025-05-09 | $3.10M derived: sum of 2 quarters · filed 2025-05-09 | $3.75M derived: sum of 3 quarters · filed 2025-05-09 | $4.49M derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | $781.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $1.43M derived: sum of 2 quarters · filed 2025-03-24 | $2.17M derived: sum of 3 quarters · filed 2025-03-24 | $2.95M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $650.00K 10-Q · filed 2024-11-18 | $1.39M derived: sum of 2 quarters · filed 2024-11-18 | $2.17M 10-Q · filed 2024-11-18 | ||
| 2023-06-30 | $743.00K 10-Q · filed 2024-08-09 | $1.52M 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | $777.00K 10-Q · filed 2024-05-10 | ||||
| 2022-12-31 | $1.34M 10-K · filed 2024-03-18 | ||||
| 2014-03-31 | $2.83K 10-Q · filed 2014-05-13 | $365.88K 10-Q · filed 2014-05-13 | |||
| 2013-03-31 | $1.45K 10-Q · filed 2014-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |